Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

7.5K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.0K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same author

Early-activated extracellular matrix proteins shape the metabolic and spatial dynamics of the kidney fibrotic microenvironment.

Nature metabolism·2026
Same author

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.

Nature medicine·2025
Same author

Hippo signaling regulates the nuclear behavior and DNA binding times of YAP and TEAD to control transcription.

Science advances·2025
Same author

Damsel: analysis and visualisation of DamID sequencing in R.

Bioinformatics (Oxford, England)·2024
Same author

Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.

EMBO reports·2024

Related Experiment Video

Updated: Sep 17, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.0K

Targeting the Hippo pathway in cancer.

Kieran F Harvey1,2,3, Tracy T Tang4

  • 1Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. kieran.harvey@petermac.org.

Nature Reviews. Drug Discovery
|June 30, 2025
PubMed
Summary

The Hippo pathway regulates tissue growth and is implicated in cancers. Inhibiting YAP/TAZ-TEAD interactions shows promise for cancer therapy, potentially combined with RAS-MAPK inhibitors.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K
Culturing and Manipulation of O9-1 Neural Crest Cells
08:32

Culturing and Manipulation of O9-1 Neural Crest Cells

Published on: October 9, 2018

10.2K

Related Experiment Videos

Last Updated: Sep 17, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.0K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K
Culturing and Manipulation of O9-1 Neural Crest Cells
08:32

Culturing and Manipulation of O9-1 Neural Crest Cells

Published on: October 9, 2018

10.2K

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncology

Background:

  • The Hippo pathway is a conserved signaling network regulating tissue growth and cell fate.
  • Aberrant Hippo signaling is linked to human diseases, especially solid cancers.
  • YAP and TAZ are key transcriptional co-activators in the Hippo pathway.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the Hippo pathway in cancer.
  • To investigate the role of YAP/TAZ-TEAD interactions in cancer progression.
  • To evaluate the combination of Hippo pathway inhibitors with RAS-MAPK inhibitors.

Main Methods:

  • Review of current literature on Hippo pathway signaling and cancer.
  • Analysis of preclinical and clinical data on Hippo pathway-targeted therapies.
  • Exploration of the functional relationship between Hippo and RAS-MAPK pathways.

Main Results:

  • Hippo pathway dysregulation is a hallmark of various cancers.
  • Inhibitors targeting YAP/TAZ-TEAD transcriptional activity show therapeutic promise.
  • TEAD inhibitors have demonstrated efficacy in early-phase clinical trials for specific cancers.
  • The Hippo pathway shares functional links with the RAS-MAPK pathway.

Conclusions:

  • Targeting the Hippo pathway, particularly YAP/TAZ-TEAD interactions, represents a viable strategy for cancer treatment.
  • Combination therapies involving Hippo pathway inhibitors and RAS-MAPK inhibitors hold significant potential for enhanced efficacy.
  • Further research into Hippo pathway modulation could lead to novel cancer therapeutics.